Sadhana Nitrochem Board Approves FY26 Audited Results, Appoints Auditors
Sadhana Nitrochem's Board approved audited standalone & consolidated results for the quarter and year ended March 31, 2026. No dividend was recommended for FY26. M/s. Chandrashekhar Iyer & Co. and M/s. Vinay Mulay & Co. were appointed as Internal and Cost Auditors, respectively, for FY27. Proceeds from the ₹251.95 Crore rights issue utilization were noted.
The approval of financial results, appointment of statutory auditors, and confirmation of rights issue fund utilization are important operational and compliance-related events for the company, impacting stakeholder confidence and regulatory adherence.
The announcement details routine financial reporting, auditor appointments, and utilization of rights issue proceeds, with no significant positive or negative surprises. The absence of a dividend recommendation is a neutral factor in this context.
Sadhana Nitro Chem Limited announced the outcome of its Board Meeting held on May 26, 2026. The Board considered and approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, along with the auditor's report. A declaration from the Managing Director confirmed an unmodified audit opinion on these results.
The Board decided not to recommend any dividend for the financial year 2025-26. In terms of appointments, M/s. Chandrashekhar Iyer & Co. were appointed as the Internal Auditor for the Financial Year 2026-27, bringing over 28 years of experience in audit and taxation. Concurrently, M/s. Vinay Mulay & Co., Cost Accountants, were appointed as the Cost Auditor for the same financial year, with Mr. Vinay Mulay possessing over 40 years of experience in various audit and financial planning fields.
Furthermore, the Board noted that the proceeds from the Rights Issue, amounting to ₹251.95 Crores, have been utilized for the intended objects as of March 31, 2026. Additionally, Mr. Vimal R. Jain, CFO & President – Operations and Finance, was appointed as a member of the Risk Management Committee. The Board Meeting commenced at 5:10 P.M. and concluded at 5:35 P.M.
What to do with a filing like this
Sadhana Nitrochem Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Sadhana Nitrochem Limited. Read the original for the full detail.